• Users Online: 154
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 8  |  Issue : 2  |  Page : 59-65

Bilastine in pruritus associated with dermatological conditions


1 Consultant Dermatologist, Skinspace Clinic, Mumbai, Maharashtra, India
2 Consultant Dermatologist, Devasya Skin Care Clinic, Mumbai, Maharashtra, India
3 Consultant Dermatologist, Skin indulgence Clinic, Mumbai, Maharashtra, India
4 Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India

Correspondence Address:
Abhay Talathi
Consultant Dermatologist, Skinspace Clinic, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdd.ijdd_18_21

Rights and Permissions

Introduction: Pruritus is a common and unpleasant symptom associated with multiple skin diseases. As histamine plays a central role in pruritus pathology, H1 antihistamines are frequently used in its management. Bilastine is a potent second-generation antihistamine approved for the management of urticaria. However, there are few studies showing its effectiveness and safety in pruritus associated with skin diseases. Materials and Methods: In this multicenter, open-label study, patients with pruritus associated with various skin diseases received bilastine 20 mg once daily for 4 weeks. Patients were evaluated for improvement in their pruritus based on the 5D itch score and Dermatology Life Quality Index (DLQI). Safety of bilastine was assessed by monitoring the incidence of adverse events during the study period. Results: A total of 116 patients with urticaria (n = 22), eczema/dermatitis (n = 27), lichen planus (n = 9), pPsoriasis (n = 11), dermatophytosis (n = 42), and others (n = 5) were included in the study. There was a significant improvement in the 5D itch score at the end of therapy (16.18 ± 2.81 vs. 6.20 ± 1.38 P < 0.0001) in all patients. Bilastine improved the DLQI at week 4 in all disease groups (11.83 ± 4.97 vs. 2.15 ± 2.68; P < 0.0001). The treatment was well tolerated. Conclusion: Bilastine is associated with significant improvement in pruritus associated with multiple dermatological disorders with a very good safety profile.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed310    
    Printed20    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal